company background image
JNJ logo

Johnson & Johnson NYSE:JNJ Stock Report

Last Price

US$160.61

Market Cap

US$385.4b

7D

-3.2%

1Y

8.0%

Updated

30 Oct, 2024

Data

Company Financials +

JNJ Stock Overview

Researches, develops, manufactures, and sells various products in the healthcare field worldwide.

JNJ fundamental analysis
Snowflake Score
Valuation4/6
Future Growth2/6
Past Performance4/6
Financial Health4/6
Dividends5/6

Community Narratives

Create a narrative

Narratives bring a range of perspectives from our community.

US$174.28
FV
7.8% undervalued intrinsic discount
3.27%
Revenue growth p.a.
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
Updated narrative
US$173.55
FV
7.5% undervalued intrinsic discount
6.30%
Revenue growth p.a.
14users have liked this narrative
0users have commented on this narrative
5users have followed this narrative
1 day ago author updated this narrative
US$133.00
FV
20.8% overvalued intrinsic discount
3.00%
Revenue growth p.a.
15users have liked this narrative
0users have commented on this narrative
4users have followed this narrative
4 months ago author updated this narrative

Johnson & Johnson Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Johnson & Johnson
Historical stock prices
Current Share PriceUS$160.61
52 Week HighUS$168.85
52 Week LowUS$143.13
Beta0.52
11 Month Change-0.89%
3 Month Change-0.093%
1 Year Change8.02%
33 Year Change-2.70%
5 Year Change22.64%
Change since IPO25,597.64%

Recent News & Updates

Johnson & Johnson: Q3 Earnings Highlights Resilience And New Growth

Oct 19

Recent updates

Johnson & Johnson: Q3 Earnings Highlights Resilience And New Growth

Oct 19

Johnson & Johnson Q3 Earnings Preview: Dividend Dependability And Steady Growth

Oct 11

Johnson & Johnson: A Sell-Rated Dividend King

Sep 23

Why Investors Shouldn't Be Surprised By Johnson & Johnson's (NYSE:JNJ) P/E

Sep 10
Why Investors Shouldn't Be Surprised By Johnson & Johnson's (NYSE:JNJ) P/E

We Think Johnson & Johnson (NYSE:JNJ) Can Stay On Top Of Its Debt

Aug 23
We Think Johnson & Johnson (NYSE:JNJ) Can Stay On Top Of Its Debt

Johnson & Johnson: Don't Bet Against Double Compounding

Aug 22

Shareholder Returns

JNJUS PharmaceuticalsUS Market
7D-3.2%-3.7%0.5%
1Y8.0%22.6%36.8%

Return vs Industry: JNJ underperformed the US Pharmaceuticals industry which returned 22.6% over the past year.

Return vs Market: JNJ underperformed the US Market which returned 36.8% over the past year.

Price Volatility

Is JNJ's price volatile compared to industry and market?
JNJ volatility
JNJ Average Weekly Movement2.0%
Pharmaceuticals Industry Average Movement9.4%
Market Average Movement6.1%
10% most volatile stocks in US Market15.0%
10% least volatile stocks in US Market3.0%

Stable Share Price: JNJ has not had significant price volatility in the past 3 months compared to the US market.

Volatility Over Time: JNJ's weekly volatility (2%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
1886131,900Joaquin Duatowww.jnj.com

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company’s Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. Its MedTech segment provides Interventional Solutions, including electrophysiology products to treat heart rhythm disorders; the heart recovery portfolio, which includes technologies to treat severe coronary artery disease requiring high-risk PCI or AMI cardiogenic shock; and neurovascular care that treats hemorrhagic and ischemic stroke.

Johnson & Johnson Fundamentals Summary

How do Johnson & Johnson's earnings and revenue compare to its market cap?
JNJ fundamental statistics
Market capUS$385.44b
Earnings (TTM)US$14.77b
Revenue (TTM)US$87.70b

26.2x

P/E Ratio

4.4x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
JNJ income statement (TTM)
RevenueUS$87.70b
Cost of RevenueUS$27.04b
Gross ProfitUS$60.65b
Other ExpensesUS$45.89b
EarningsUS$14.77b

Last Reported Earnings

Sep 29, 2024

Next Earnings Date

Jan 22, 2025

Earnings per share (EPS)6.13
Gross Margin69.16%
Net Profit Margin16.84%
Debt/Equity Ratio51.0%

How did JNJ perform over the long term?

See historical performance and comparison

Dividends

3.1%

Current Dividend Yield

79%

Payout Ratio

Does JNJ pay a reliable dividends?

See JNJ dividend history and benchmarks
When do you need to buy JNJ by to receive an upcoming dividend?
Johnson & Johnson dividend dates
Ex Dividend DateNov 26 2024
Dividend Pay DateDec 10 2024
Days until Ex dividend26 days
Days until Dividend pay date40 days

Does JNJ pay a reliable dividends?

See JNJ dividend history and benchmarks